NEW YORK (GenomeWeb) – Myriad Genetics has submitted BRACAnalysis CDx for review by Japan's Pharmaceutical Medical Devices Agency and for marketing approval by its Ministry of Health, Labor and Welfare.

If approved, the companion diagnostic can be used to identify which HER2-negative, metastatic breast cancer patients have germline mutations in BRCA1 and BRCA2 genes and are likely to respond to AstraZeneca's Lynparza (olaparib).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Dec
06

Rhythm Pharmaceuticals and Genomenon will discuss their efforts to assemble a database of mutations associated with rare genetic disorders of obesity, and how this was optimized to facilitate a deep understanding of the variant landscape of melanocortin-4 receptor (MC4R)-pathway genes. This database may help identify MC4R-pathway deficient individuals who might benefit from future precision therapies.